The PrEP-LANA study (Pre-Exposure Prophylaxis with a Long-Acting Novel Antiviral Agent) is a UK-wide research study led by the SHARE Collaborative at Queen Mary University of London. The study aims to understand how best to deliver long-acting injectable PrEP (cabotegravir) within NHS sexual health services in a way that is effective, accessible, and equitable for everyone who could benefit from it.
PrEP (Pre-Exposure Prophylaxis) is highly effective at preventing HIV. While daily oral PrEP works well for many people, some find it difficult to take tablets consistently. Long-acting injectable PrEP, known as CAB-LA or cabotegravir, offers an alternative by providing HIV prevention through an injection administered every two months as part of routine NHS care.
Long-acting injectable PrEP has been shown to be safe and effective, but there is limited evidence about the best ways to introduce and deliver this new prevention option across different NHS settings and communities. PrEP-LANA seeks to address this evidence gap by examining how injectable PrEP is implemented in real-world healthcare settings and identifying approaches that support equitable access and positive experiences for patients and healthcare professionals.
The study has a particular focus on understanding how services can meet the needs of people and communities who have historically experienced barriers to accessing PrEP and HIV prevention services.
PrEP-LANA will work with people using injectable PrEP and healthcare professionals involved in its delivery to understand:
The study will recruit approximately 220 participants, including PrEP users and healthcare professionals, across participating NHS sexual health services in England and Wales.
PrEP-LANA is sponsored by Queen Mary University of London and is led by Professor Chloe Orkin through the SHARE Collaborative, a research team committed to reducing health inequalities and improving equitable access to healthcare innovations. The study builds on SHARE’s wider programme of work exploring how long-acting HIV prevention and treatment options can be implemented in ways that work for diverse communities across the UK.
Please see our explainer video below for more information on the study.
Further information about participating sites, study updates, and opportunities to get involved will be shared as the study progresses. We look forward to working with communities, healthcare professionals, and partner organisations to help shape the future of HIV prevention services in the UK.
